Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Deborah Collyar: What's In It for Patients?

Apr

Today In Oncology

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Deborah Collyar: What's In It for Patients?

Melanoma Can AI Enable Diagnosis Prediction

AI Tool Shows Early Ability in Pinpointing Cells Driving Aggressive Cancers

DRUP Trial Investigates Use of Off-Label Drugs for Patients With Advanced Solid Tumors

Sequential or Concurrent Radiotherapy and Immunotherapy in Advanced Newly Diagnosed or Refractory NSCLC

Romiplostim for Chemotherapy-Induced Thrombocytopenia